AbbVie’s medical aesthetics division Allergan may not get the makeover it was counting on this year if the Federal Trade Commission (FTC) has anything to say about it.

The FTC has asked Allergan to submit additional information about its plan to buy devicemaker Soliton, according to documents Soliton filed with the Securities and Exchange Commission (SEC) on Aug. 6. The so-called “second request” indicates the FTC is launching a deeper probe than its standard review of merger proposals, sparked by potential antitrust concerns.

Read the full article at